325 related articles for article (PubMed ID: 18314475)
1. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.
Merritt WM; Lin YG; Spannuth WA; Fletcher MS; Kamat AA; Han LY; Landen CN; Jennings N; De Geest K; Langley RR; Villares G; Sanguino A; Lutgendorf SK; Lopez-Berestein G; Bar-Eli MM; Sood AK
J Natl Cancer Inst; 2008 Mar; 100(5):359-72. PubMed ID: 18314475
[TBL] [Abstract][Full Text] [Related]
2. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.
Nick AM; Stone RL; Armaiz-Pena G; Ozpolat B; Tekedereli I; Graybill WS; Landen CN; Villares G; Vivas-Mejia P; Bottsford-Miller J; Kim HS; Lee JS; Kim SM; Baggerly KA; Ram PT; Deavers MT; Coleman RL; Lopez-Berestein G; Sood AK
J Natl Cancer Inst; 2011 Nov; 103(21):1596-612. PubMed ID: 21957230
[TBL] [Abstract][Full Text] [Related]
3. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.
Halder J; Kamat AA; Landen CN; Han LY; Lutgendorf SK; Lin YG; Merritt WM; Jennings NB; Chavez-Reyes A; Coleman RL; Gershenson DM; Schmandt R; Cole SW; Lopez-Berestein G; Sood AK
Clin Cancer Res; 2006 Aug; 12(16):4916-24. PubMed ID: 16914580
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
5. Functional roles of Src and Fgr in ovarian carcinoma.
Kim HS; Han HD; Armaiz-Pena GN; Stone RL; Nam EJ; Lee JW; Shahzad MM; Nick AM; Lee SJ; Roh JW; Nishimura M; Mangala LS; Bottsford-Miller J; Gallick GE; Lopez-Berestein G; Sood AK
Clin Cancer Res; 2011 Apr; 17(7):1713-21. PubMed ID: 21300758
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.
Landen CN; Chavez-Reyes A; Bucana C; Schmandt R; Deavers MT; Lopez-Berestein G; Sood AK
Cancer Res; 2005 Aug; 65(15):6910-8. PubMed ID: 16061675
[TBL] [Abstract][Full Text] [Related]
7. Dual targeting of EphA2 and FAK in ovarian carcinoma.
Shahzad MM; Lu C; Lee JW; Stone RL; Mitra R; Mangala LS; Lu Y; Baggerly KA; Danes CG; Nick AM; Halder J; Kim HS; Vivas-Mejia P; Landen CN; Lopez-Berestein G; Coleman RL; Sood AK
Cancer Biol Ther; 2009 Jun; 8(11):1027-34. PubMed ID: 19395869
[TBL] [Abstract][Full Text] [Related]
8. Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer.
Gharpure KM; Chu KS; Bowerman CJ; Miyake T; Pradeep S; Mangala SL; Han HD; Rupaimoole R; Armaiz-Pena GN; Rahhal TB; Wu SY; Luft JC; Napier ME; Lopez-Berestein G; DeSimone JM; Sood AK
Mol Cancer Ther; 2014 Jul; 13(7):1750-7. PubMed ID: 24755199
[TBL] [Abstract][Full Text] [Related]
9. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells.
Halder J; Landen CN; Lutgendorf SK; Li Y; Jennings NB; Fan D; Nelkin GM; Schmandt R; Schaller MD; Sood AK
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8829-36. PubMed ID: 16361572
[TBL] [Abstract][Full Text] [Related]
10. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer.
Steg AD; Katre AA; Goodman B; Han HD; Nick AM; Stone RL; Coleman RL; Alvarez RD; Lopez-Berestein G; Sood AK; Landen CN
Clin Cancer Res; 2011 Sep; 17(17):5674-85. PubMed ID: 21753153
[TBL] [Abstract][Full Text] [Related]
11. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK
Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer.
Landen CN; Merritt WM; Mangala LS; Sanguino AM; Bucana C; Lu C; Lin YG; Han LY; Kamat AA; Schmandt R; Coleman RL; Gershenson DM; Lopez-Berestein G; Sood AK
Cancer Biol Ther; 2006 Dec; 5(12):1708-13. PubMed ID: 17106249
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.
Halder J; Lin YG; Merritt WM; Spannuth WA; Nick AM; Honda T; Kamat AA; Han LY; Kim TJ; Lu C; Tari AM; Bornmann W; Fernandez A; Lopez-Berestein G; Sood AK
Cancer Res; 2007 Nov; 67(22):10976-83. PubMed ID: 18006843
[TBL] [Abstract][Full Text] [Related]
14. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.
Lin YG; Kunnumakkara AB; Nair A; Merritt WM; Han LY; Armaiz-Pena GN; Kamat AA; Spannuth WA; Gershenson DM; Lutgendorf SK; Aggarwal BB; Sood AK
Clin Cancer Res; 2007 Jun; 13(11):3423-30. PubMed ID: 17545551
[TBL] [Abstract][Full Text] [Related]
15. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.
Shen H; Rodriguez-Aguayo C; Xu R; Gonzalez-Villasana V; Mai J; Huang Y; Zhang G; Guo X; Bai L; Qin G; Deng X; Li Q; Erm DR; Aslan B; Liu X; Sakamoto J; Chavez-Reyes A; Han HD; Sood AK; Ferrari M; Lopez-Berestein G
Clin Cancer Res; 2013 Apr; 19(7):1806-15. PubMed ID: 23386691
[TBL] [Abstract][Full Text] [Related]
16. Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer.
Vivas-Mejia PE; Rodriguez-Aguayo C; Han HD; Shahzad MM; Valiyeva F; Shibayama M; Chavez-Reyes A; Sood AK; Lopez-Berestein G
Clin Cancer Res; 2011 Jun; 17(11):3716-26. PubMed ID: 21512144
[TBL] [Abstract][Full Text] [Related]
17. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.
Lee JW; Han HD; Shahzad MM; Kim SW; Mangala LS; Nick AM; Lu C; Langley RR; Schmandt R; Kim HS; Mao S; Gooya J; Fazenbaker C; Jackson D; Tice DA; Landen CN; Coleman RL; Sood AK
J Natl Cancer Inst; 2009 Sep; 101(17):1193-205. PubMed ID: 19641174
[TBL] [Abstract][Full Text] [Related]
18. Sustained small interfering RNA delivery by mesoporous silicon particles.
Tanaka T; Mangala LS; Vivas-Mejia PE; Nieves-Alicea R; Mann AP; Mora E; Han HD; Shahzad MM; Liu X; Bhavane R; Gu J; Fakhoury JR; Chiappini C; Lu C; Matsuo K; Godin B; Stone RL; Nick AM; Lopez-Berestein G; Sood AK; Ferrari M
Cancer Res; 2010 May; 70(9):3687-96. PubMed ID: 20430760
[TBL] [Abstract][Full Text] [Related]
19. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis.
Shahzad MM; Arevalo JM; Armaiz-Pena GN; Lu C; Stone RL; Moreno-Smith M; Nishimura M; Lee JW; Jennings NB; Bottsford-Miller J; Vivas-Mejia P; Lutgendorf SK; Lopez-Berestein G; Bar-Eli M; Cole SW; Sood AK
J Biol Chem; 2010 Nov; 285(46):35462-70. PubMed ID: 20826776
[TBL] [Abstract][Full Text] [Related]
20. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.
Lin YG; Immaneni A; Merritt WM; Mangala LS; Kim SW; Shahzad MM; Tsang YT; Armaiz-Pena GN; Lu C; Kamat AA; Han LY; Spannuth WA; Nick AM; Landen CN; Wong KK; Gray MJ; Coleman RL; Bodurka DC; Brinkley WR; Sood AK
Clin Cancer Res; 2008 Sep; 14(17):5437-46. PubMed ID: 18765535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
